First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma to Participate in Maxim’s 2022 Virtual Growth Conference
March 22, 2022 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., March 22, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma to Participate in ”Fireside Chat” at the 34th Annual Roth Conference
March 08, 2022 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Announces Poster Presentation at the 2022 Digestive Disease Week (DDW) Conference
March 03, 2022 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Announces Appointment of Sarah Romano as Chief Financial Officer
March 01, 2022 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., March 01, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma, Inc. Announces $9 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
February 28, 2022 08:01 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted,...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections
January 06, 2022 07:00 ET | First Wave BioPharma, Inc.
No Drug-Related SAEs Reported; Topline Data Expected 1H 2022 Part 2 of RESERVOIR Trial to Evaluate Efficacy of FW-COV, an Oral Formulation of Niclosamide, and Expand Safety Observations on...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma to Participate in Two Investor Conferences in January 2022
January 04, 2022 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 04, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders
December 13, 2021 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Announces Two Additions to Scientific Advisory Board
October 12, 2021 08:30 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 12, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 16:30 ET | AzurRx BioPharma, Inc.
BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies...